Shaw's Eco-Logic

Lung cancer is the leading cause of cancer-related mortality in both men and women in the United States and throughout the world. Sadly, most cases of lung cancer are diagnosed at an advanced stage, conferring a poor prognosis.

As it is, only about 16% of NSCLC patients are diagnosed early enough to be eligible for surgery. Most of the rest undergo some form of chemotherapy. Overall, fewer than 5% of advanced non-small cell lung cancer patients survive five years.

My latest HND piece looks at a possible breakthrough drug, that seems to make chemotherapy agents work better, and be tolerated better by the patient, as well. The drug is NOV-002, from Novelos Therapeutics, Inc., a New England-based biopharmaceutical company.

I also cover the types of Clinical trials, noting that NOV-002 is now approaching the end of a Phase III trail, and mention two other promising ways that chemo efficacy can be improved.

Read the complete article.